Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Purpose: To report the occurrence of multiple bilateral retinal breaks 11 years after bevacizumab treatment for retinopathy of prematurity (ROP).
Methods: A case report.
Results: An 11-year-old girl developed multiple bilateral retinal breaks in areas of vitreous condensation 11 years after treatment for ROP with intravitreal bevacizumab at 4 months of age. The retinal breaks were treated with laser retinopexy as prophylaxis for retinal detachment.
Discussion: Patients with a history of ROP have a lifelong increased risk of retinal tears, and the long-term effects of intravitreal anti-vascular endothelial growth factor therapy for ROP are not well understood or documented. It is unknown whether there are differences in the rates of long-term ocular complications of ROP after anti-vascular endothelial growth factor versus laser treatment of ROP. Studies are needed to compare the long-term benefits and risks associated with both approaches.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/ICB.0000000000001035 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!